BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IntraBiotics Pharmaceuticals, Inc. (IBPI) Provides Additional Update On Pending Litigation


8/7/2006 10:15:15 AM

LAFAYETTE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- IntraBiotics Pharmaceuticals, Inc. today reported on a recent U.S. District Court order in IntraBiotics' pending litigation filed in July 2004.

As we previously reported, on January 23, 2006, the U.S. District Court granted the motion of IntraBiotics and individual defendants to dismiss, with leave to amend, the plaintiffs' amended complaint with respect to claims under the Securities Exchange Act of 1934 ("1934 Act Claims"), and denied the motion to dismiss the claims under the Securities Act of 1933 ("1933 Act Claims"). On February 22, 2006, plaintiffs filed a second amended complaint.

On August 1, 2006, the Court issued an order granting IntraBiotics' and the individual defendants' motion to dismiss the 1934 Act Claims in the second amended complaint, with prejudice. In its opinion, the Court concluded that Plaintiffs failed to allege sufficient facts to support a material misstatement or omission with respect to the 1934 Act Claims. With respect to the 1933 Act Claims, the Court gave the parties the opportunity to provide supplemental briefs before it would rule on these claims.

The Company believes the suit to be without merit and intends to defend itself vigorously. Due to the uncertainties surrounding the final outcome of this matter, no amounts have been accrued by the Company. The Company and the individual defendants are insured under the Company's directors' and officers' insurance policies, with $15 million in total coverage, and a $500,000 deductible, which has been met. Nevertheless, the Company may incur expenses in the defense or disposition of the litigation beyond what is covered by insurance.

For further information concerning the shareholder suit, see IntraBiotics' annual report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2006 and the 2006 2nd quarterly report on Form 10-Q filed with the Securities and Exchange Commission on July 28, 2006.

IntraBiotics Pharmaceuticals, Inc.

CONTACT: Denis Hickey of IntraBiotics Pharmaceuticals, Inc.,+1-925-906-5331



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES